000 01343 a2200385 4500
005 20250511212652.0
264 0 _c19911028
008 199110s 0 0 eng d
022 _a0162-3109
024 7 _a10.1016/0162-3109(91)90025-t
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aD'Atri, S
245 0 0 _aDrug-mediated increase of susceptibility of human lung cancer to NK or LAK effector cells.
_h[electronic resource]
260 _bImmunopharmacology
_c
300 _a199-210 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAntigens, Neoplasm
650 0 4 _aAntineoplastic Agents
_xpharmacology
650 0 4 _aCell Line
650 0 4 _aCytotoxicity, Immunologic
650 0 4 _aHLA Antigens
650 0 4 _aHumans
650 0 4 _aKiller Cells, Lymphokine-Activated
_ximmunology
650 0 4 _aKiller Cells, Natural
_ximmunology
650 0 4 _aLung Neoplasms
_xdrug therapy
650 0 4 _aTriazenes
_xpharmacology
650 0 4 _aTumor Cells, Cultured
_xdrug effects
700 1 _aMarini, S
700 1 _aTentori, L
700 1 _aTricarico, M
700 1 _aFuggetta, M P
700 1 _aBonmassar, E
773 0 _tImmunopharmacology
_gvol. 21
_gno. 3
_gp. 199-210
856 4 0 _uhttps://doi.org/10.1016/0162-3109(91)90025-t
_zAvailable from publisher's website
999 _c1923646
_d1923646